|
Carcinoma of bladder
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We analyzed the possible prognostic value of the recently discovered fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer.
|
11245416 |
2001 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We recently identified activating mutations of fibroblast growth factor receptor 3 (FGFR3) in bladder carcinoma.
|
11395371 |
2001 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma.
|
11466624 |
2001 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In view of these findings, the authors investigated the incidence of TD mutations in the FGFR3 gene in a large series of bladder carcinomas to clarify their role in the progression of bladder carcinoma.
|
11745189 |
2001 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recently, activating FGFR3 mutations have also been found to be present in cancer, i.e. at high frequency in carcinoma of the bladder and rarely in multiple myeloma and carcinoma of the cervix.
|
12461689 |
2002 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
|
14678961 |
2003 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the FGFR3 and TP53 genes have been shown to define two distinct pathways in superficial papillary and invasive UCC disease, respectively.
|
15347601 |
2005 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we looked for FGFR3 mutations in these two animal models of bladder cancer.
|
15690367 |
2005 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 and Tp53 mutations have been proposed as defining two alternative pathways in the pathogenesis of transitional bladder cancer.
|
16061860 |
2005 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results suggest that these human anti-FGFR3 scFv antibodies may have potential applications as antitumoral agents in bladder cancer.
|
16144932 |
2005 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this clinical follow-up study was to investigate the role of FGFR3 mutations in bladder cancer development in a longitudinal study.
|
16278391 |
2005 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.
|
16278395 |
2005 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
In summary, alternative splicing of FGFR3 IIIb in NHU cells represents a normal mechanism to generate a transcript that regulates proliferation and in bladder cancer, the ratio of FGFR3 isoforms is significantly altered.
|
16288035 |
2005 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
An example of a TM domain pathogenic mutation is the Ala391-->Glu mutation in fibroblast growth factor receptor 3 (FGFR3), linked to Crouzon syndrome with acanthosis nigricans, as well as to bladder cancer.
|
16384584 |
2006 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The detection of FGFR3 mutations in FUH further supports the role of this lesion as precursor of papillary bladder cancer.
|
16570285 |
2006 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations of FGFR3 have been identified in bladder cancer, multiple myeloma, and other neoplasms.
|
16778799 |
2006 |
|
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The phenotypic consequences of constitutive activation of FGFR3 in bladder cancer have not been elucidated and further studies are required to confirm the consequences of inhibiting receptor activity in urothelial cells.
|
17384684 |
2007 |
|
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.
|
17668422 |
2007 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, several FGFRs are mutated in human cancers (including FGFR2 in gastric cancer and FGFR3 in bladder cancer).
|
17697126 |
2007 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping.
|
17803960 |
2007 |
|
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
|
18413799 |
2008 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The two most important developments are the identification of a mutation in the fibroblast growth factor receptor 3 gene in more than 50% of urothelial carcinomas and the discovery of cDNA profiles characteristic of different subsets of bladder cancer.
|
19031931 |
2009 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
These studies provide in vivo evidence demonstrating an oncogenic role of FGFR3 in bladder cancer and support antibody-based targeting of FGFR3 in hematologic and epithelial cancers driven by WT or mutant FGFR3.
|
19381019 |
2009 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
|
19381019 |
2009 |